$33.04
0.55 (+1.69%)
Mindray Medical International Limited (MR)
CAPS Rating:
The Company is a developer, manufacturer and marketer of medical devices in China.
Fool.com
The World's Greatest Investing Community
RSS Headlines
Fool UK
Recs
Competive advantages, dedication to R&D, BOTH Chinese and international markets / sales force, stellar management (all things considered), good balance sheet/financial health, and in a sector which is growing by leaps and bounds (tho margins may decline).
Any wonder this is my 4th re-up? Yes, things may stagnate here for a while during the DataScope integration, but I can wait til '09 for increased earnings and cross-selling to become accretive. Analysts are saying 40-45% annual eps growth. I'd settle for 25% with a company of this quality and in this sector.
I don't regret taking some profits off the table since the IPO. But, I think I just might settle in here for the long haul.
DataScope aquisition seems like a great move aquiring a US sales force!
Totally agree with you. I haven't found much with which to fault MR's execution thus far. Hope they keep it up!
Mindray Medical International Limited New guidance:Revenue: in the range of $560-$580 million (Old mean estimate $455)EPS: in the range of $1.15-$1.17 (Old mean estimate $1.05)Analyst seriously need to re-evaluate their models based on current assumptions.
I seem to always agree with you !!!!MR is now a global force/company. Sit tight. We are witnessing something remarkable ... me thinks.Thanks for doing the heavy lifting on the current #'s, gX. The analysts are behind on this one (BIG TIME).
Acquisitions are being digested quickly (and without any apparent heartburn)! FDA approvals are rolling in. Management is being upgraded (especially internationally).I'm upgrading from medium term ... to long term buy and hold today. The only reason I was reluctant before is that Mindray is a "story stock" and we all know what that means to stock prices on a weekly, monthly and quarterly basis. Well, I'm committed now.